BBPC-157· Health · 5 sources · Sep 15, 2026StoryStudy Finds 33-Fold Rise in BPC-157 Use Despite Limited Safety DataBPC-157, an unapproved peptide backed by RFK Jr. and often used with TB-500 as the “Wolverine stack,” is being consumed across a wide range of conditions in the gray market, with new-user numbers rising 33-fold from 2020 to 2026 and regulation still unresolved as the FDA weighs compounding despite safety concerns. Researchers warn that real-world use is hard to track, 1,039 documented patients exist, and there is no solid evidence that the peptide improves healing or pain, underscoring safety risks amid burgeoning popularity.Health· Sep 15, 2026+20CommentShareWrite a comment…
BBPC-157· Health · 9 sources · Jul 23, 2026StoryFDA panel backs BPC-157 access, Hims shares surgeAn FDA advisory panel recommended adding BPC-157 to the list eligible for pharmacy compounding, a move investors interpreted as a boost to Hims & Hers' telehealth and peptide offerings, with the stock jumping about 10–11% across reports. The company, valued around $8.1 billion, has faced insider selling in the past quarter, and regulators’ signaling comes as it positions itself in a growing peptide therapy market.Health· Jul 23, 2026+60CommentShareWrite a comment…
